| 摘要 |
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., ankylosing spondylitis (AS) or psoriatic arthritis (PsA) which employ a therapeutically effective amount of an IL-17 antagonist, e.g., 1L-1 7 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL- 17 antibody or antigen binding fragment thereof). |
